サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1530970

不活化ワクチン市場：世界の産業分析、規模、シェア、成長、動向、2024年～2034年予測

Inactivated Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 167 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
不活化ワクチン市場：世界の産業分析、規模、シェア、成長、動向、2024年～2034年予測
出版日: 2024年06月21日
発行: Transparency Market Research
ページ情報: 英文 167 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

不活化ワクチン市場- 調査範囲

TMRの調査レポート「不活化ワクチンの世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の不活化ワクチン市場の収益と予測を提供しています。また、2024年から2034年までの世界の不活化ワクチン市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、不活化ワクチン市場を推察しました。

市場スナップショット
2023年の市場規模 406億米ドル
2034年の市場規模 748億米ドル
CAGR 5.7%

本レポートでは、世界の不活化ワクチン市場の競合情勢について掘り下げています。世界の不活化ワクチン市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の不活化ワクチン市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測、2020年～2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界の市場分析と予測：ワクチンの種類別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：ワクチンの種類別、2020年～2034年
    • ウイルスワクチン
    • 細菌ワクチン
  • 市場の魅力：ワクチン種別

第7章 世界の市場分析と予測：不活化法別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：不活化法別、2020年～2034年
    • 溶剤洗剤法
    • 放射線法
    • pH濃度
    • その他（加熱不活化等）
  • 市場の魅力：不活化法別

第8章 世界の市場分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：投与経路別、2020年～2034年
    • 経口
    • 皮下
    • 静脈内
  • 市場の魅力：投与経路別

第9章 世界の市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：エンドユーザー別、2020年～2034年
    • 病院
    • 専門クリニック
    • ホームケア設定
    • その他（研究センター等）
  • 市場の魅力：エンドユーザー別

第10章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020年～2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第11章 北米の市場分析と予測

第12章 欧州の市場分析と予測

第13章 アジア太平洋地域の市場分析と予測

第14章 ラテンアメリカの市場分析と予測

第15章 中東・アフリカの市場分析と予測

第16章 競合情勢

  • 市場企業-競合マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • GSK plc
    • Novartis AG
    • Mylan N.V.
    • Sanofi S.A.
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb Company
    • Bharat Biotech
    • Serum Institute of India
    • INOVIO Pharmaceuticals, Inc.
図表

List of Tables

  • Table 01: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 02: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 03: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 04: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Inactivated Vaccines Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 06: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 07: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 08: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 09: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 11: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 13: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 14: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 16: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 18: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 19: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 21: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 23: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 24: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 26: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Vaccine Type, 2020-2034
  • Table 28: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Method of Inactivation, 2020-2034
  • Table 29: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Inactivated Vaccines Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 02: Global Inactivated Vaccines Market Revenue (US$ Bn), by Vaccine Type, 2023
  • Figure 03: Global Inactivated Vaccines Market Value Share, by Vaccine Type, 2023
  • Figure 04: Global Inactivated Vaccines Market Revenue (US$ Bn), by Method of Inactivation, 2023
  • Figure 05: Global Inactivated Vaccines Market Value Share, by Method of Inactivation, 2023
  • Figure 06: Global Inactivated Vaccines Market Revenue (US$ Bn), by Route of Administration, 2023
  • Figure 07: Global Inactivated Vaccines Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Inactivated Vaccines Market Revenue (US$ Bn), by End-user, 2023
  • Figure 09: Global Inactivated Vaccines Market Value Share, by End-user, 2023
  • Figure 10: Global Inactivated Vaccines Market Value Share, by Region, 2023
  • Figure 11: Global Inactivated Vaccines Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 13: Global Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 14: Global Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 15: Global Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 16: Global Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Inactivated Vaccines Market Revenue (US$ Bn), by End-user, 2023
  • Figure 19: Global Inactivated Vaccines Market Value Share, by End-user, 2023
  • Figure 20: Global Inactivated Vaccines Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Inactivated Vaccines Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Inactivated Vaccines Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Inactivated Vaccines Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 26: North America Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 27: North America Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 29: North America Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 30: North America Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 31: North America Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 37: Europe Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 38: Europe Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Europe Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 41: Europe Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 42: Europe Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 48: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 49: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 52: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 53: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Inactivated Vaccines Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 59: Latin America Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 60: Latin America Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 63: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 64: Latin America Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Inactivated Vaccines Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Vaccine Type, 2023 and 2034
  • Figure 70: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Method of Inactivation, 2023 and 2034
  • Figure 71: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Inactivated Vaccines Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 73: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Vaccine Type, 2024-2034
  • Figure 74: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Method of Inactivation, 2024-2034
  • Figure 75: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Inactivated Vaccines Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL31316

Inactivated Vaccines Market - Scope of Report

TMR's report on the global inactivated vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global inactivated vaccines market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global inactivated vaccines market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the inactivated vaccines market.

Market Snapshot
Market Value in 2023US$ 40.6 Bn
Market Value in 2034US$ 74.8 Bn
CAGR5.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global inactivated vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global inactivated vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global inactivated vaccines market.

The report delves into the competitive landscape of the global inactivated vaccines market. Key players operating in the global inactivated vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global inactivated vaccines market profiled in this report.

Key Questions Answered in Global inactivated vaccines Market Report:

  • What is the sales/revenue generated by inactivated vaccines across all regions during the forecast period?
  • What are the opportunities in the global inactivated vaccines market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Inactivated Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global inactivated vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global inactivated vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global inactivated vaccines market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Inactivated Vaccines Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Inactivated Vaccines Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Inactivated Vaccines Market Analysis and Forecast, by Vaccine Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Vaccine Type, 2020-2034
    • 6.3.1. Viral Vaccine
    • 6.3.2. Bacterial Vaccine
  • 6.4. Market Attractiveness, by Vaccine Type

7. Global Inactivated Vaccines Market Analysis and Forecast, by Method of Inactivation

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 7.3.1. Solvent Detergent Method
    • 7.3.2. Radiation Method
    • 7.3.3. pH Concentration
    • 7.3.4. Others (Heat Inactivation, etc.)
  • 7.4. Market Attractiveness, by Method of Inactivation

8. Global Inactivated Vaccines Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Oral
    • 8.3.2. Subcutaneous
    • 8.3.3. Intravenous
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Inactivated Vaccines Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020-2034
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Homecare Settings
    • 9.3.4. Others (Research Centers, etc.)
  • 9.4. Market Attractiveness, by End-user

10. Global Inactivated Vaccines Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Inactivated Vaccines Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 11.2.1. Viral Vaccine
    • 11.2.2. Bacterial Vaccine
  • 11.3. Market Attractiveness, by Vaccine Type
  • 11.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 11.4.1. Solvent Detergent Method
    • 11.4.2. Radiation Method
    • 11.4.3. pH Concentration
    • 11.4.4. Others (Heat Inactivation, etc.)
  • 11.5. Market Attractiveness, by Method of Inactivation
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Oral
    • 11.6.2. Subcutaneous
    • 11.6.3. Intravenous
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by End-user, 2020-2034
    • 11.8.1. Hospitals
    • 11.8.2. Specialty Clinics
    • 11.8.3. Homecare Settings
    • 11.8.4. Others (Research Centers, etc.)
  • 11.9. Market Attractiveness, by End-user
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Vaccine Type
    • 11.11.2. By Method of Inactivation
    • 11.11.3. By Route of Administration
    • 11.11.4. By End-user
    • 11.11.5. By Country

12. Europe Inactivated Vaccines Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 12.2.1. Viral Vaccine
    • 12.2.2. Bacterial Vaccine
  • 12.3. Market Attractiveness, by Vaccine Type
  • 12.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 12.4.1. Solvent Detergent Method
    • 12.4.2. Radiation Method
    • 12.4.3. pH Concentration
    • 12.4.4. Others (Heat Inactivation, etc.)
  • 12.5. Market Attractiveness, by Method of Inactivation
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Oral
    • 12.6.2. Subcutaneous
    • 12.6.3. Intravenous
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by End-user, 2020-2034
    • 12.8.1. Hospitals
    • 12.8.2. Specialty Clinics
    • 12.8.3. Homecare Settings
    • 12.8.4. Others (Research Centers, etc.)
  • 12.9. Market Attractiveness, by End-user
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Vaccine Type
    • 12.11.2. By Method of Inactivation
    • 12.11.3. By Route of Administration
    • 12.11.4. By End-user
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Inactivated Vaccines Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 13.2.1. Viral Vaccine
    • 13.2.2. Bacterial Vaccine
  • 13.3. Market Attractiveness, by Vaccine Type
  • 13.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 13.4.1. Solvent Detergent Method
    • 13.4.2. Radiation Method
    • 13.4.3. pH Concentration
    • 13.4.4. Others (Heat Inactivation, etc.)
  • 13.5. Market Attractiveness, by Method of Inactivation
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Oral
    • 13.6.2. Subcutaneous
    • 13.6.3. Intravenous
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by End-user, 2020-2034
    • 13.8.1. Hospitals
    • 13.8.2. Specialty Clinics
    • 13.8.3. Homecare Settings
    • 13.8.4. Others (Research Centers, etc.)
  • 13.9. Market Attractiveness, by End-user
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Vaccine Type
    • 13.11.2. By Method of Inactivation
    • 13.11.3. By Route of Administration
    • 13.11.4. By End-user
    • 13.11.5. By Country/Sub-region

14. Latin America Inactivated Vaccines Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 14.2.1. Viral Vaccine
    • 14.2.2. Bacterial Vaccine
  • 14.3. Market Attractiveness, by Vaccine Type
  • 14.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 14.4.1. Solvent Detergent Method
    • 14.4.2. Radiation Method
    • 14.4.3. pH Concentration
    • 14.4.4. Others (Heat Inactivation, etc.)
  • 14.5. Market Attractiveness, by Method of Inactivation
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Oral
    • 14.6.2. Subcutaneous
    • 14.6.3. Intravenous
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by End-user, 2020-2034
    • 14.8.1. Hospitals
    • 14.8.2. Specialty Clinics
    • 14.8.3. Homecare Settings
    • 14.8.4. Others (Research Centers, etc.)
  • 14.9. Market Attractiveness, by End-user
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Vaccine Type
    • 14.11.2. By Method of Inactivation
    • 14.11.3. By Route of Administration
    • 14.11.4. By End-user
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Inactivated Vaccines Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Vaccine Type, 2020-2034
    • 15.2.1. Viral Vaccine
    • 15.2.2. Bacterial Vaccine
  • 15.3. Market Attractiveness, by Vaccine Type
  • 15.4. Market Value Forecast, by Method of Inactivation, 2020-2034
    • 15.4.1. Solvent Detergent Method
    • 15.4.2. Radiation Method
    • 15.4.3. pH Concentration
    • 15.4.4. Others (Heat Inactivation, etc.)
  • 15.5. Market Attractiveness, by Method of Inactivation
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Oral
    • 15.6.2. Subcutaneous
    • 15.6.3. Intravenous
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by End-user, 2020-2034
    • 15.8.1. Hospitals
    • 15.8.2. Specialty Clinics
    • 15.8.3. Homecare Settings
    • 15.8.4. Others (Research Centers, etc.)
  • 15.9. Market Attractiveness, by End-user
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Vaccine Type
    • 15.11.2. By Method of Inactivation
    • 15.11.3. By Route of Administration
    • 15.11.4. By End-user
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. GSK plc
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Novartis AG
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Mylan N.V.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Sanofi S.A.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Boehringer Ingelheim International GmbH
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co., Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. F. Hoffmann-La Roche AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Bristol-Myers Squibb Company
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Bharat Biotech
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Serum Institute of India
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. INOVIO Pharmaceuticals, Inc.
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview